Neuronetics, Inc.

Equities

STIM

US64131A1051

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-13 pm EST			5-day change	1st Jan Change
1.420 ^USD	-10.13%		-8.97%	+2.90%

Feb. 10	Neuronetics Reports Preliminary Fiscal Q4, 2025 Results	MT
Nov. 04	Neuronetics, Inc., Q3 2025 Earnings Call, Nov 04, 2025

Neuronetics, Inc. Provides Earnings Guidance for the Full Year 2025

Published on 01/13/2025 at 08:00 am EST

S&P Capital IQ

NEURONETICS, INC.

-10.13%

Neuronetics, Inc. provided earnings guidance for the full year 2025. For the year, the company expects Total Revenue of $145.0 million to $155.0 million (+12% to 19% on a proforma basis). Gross margin expected to be approximately 55%.

Latest news about Neuronetics, Inc.

Feb. 10	Neuronetics Reports Preliminary Fiscal Q4, 2025 Results	MT
Nov. 04	Neuronetics, Inc., Q3 2025 Earnings Call, Nov 04, 2025
Nov. 04	Neuronetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 04	Keith J. Sullivan Intends to Retire as Chief Executive Officer of Neuronetics, Inc. on June 30, 2026	CI
Nov. 04	Neuronetics, Inc. Provides Revenue Guidance for the Fourth Quarter 2025	CI
Nov. 04	Neuronetics, Inc. Revises Earnings Guidance for the Full Year 2025	CI
25-10-30	Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand Neurostar Access and Operational Excellence	CI
25-09-21	Neuronetics, Inc.(NasdaqGM:STIM) added to S&P Global BMI Index	CI
25-09-17	Neuronetics - New York Medicaid to cover TMS services for adults with MDD	RE
25-08-05	Neuronetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-05	Neuronetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year Ending December 31, 2025	CI
25-07-15	Neuronetics appoints new chief financial officer	RE
25-07-15	Neuronetics, Inc. Appoints Steven Pfanstiel as Executive Vice President, and Treasurer	CI
25-06-30	Neuronetics, Inc.(NasdaqGM:STIM) added to Russell 3000 Growth Index	CI
25-06-30	Neuronetics, Inc.(NasdaqGM:STIM) added to Russell 2000 Dynamic Index	CI

Chart Neuronetics, Inc.

Duration

Period

STIM: Dynamic Chart

Company Profile

Neuronetics, Inc. is a commercial-stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.

Employees

716

Sector

Advanced Medical Equipment & Technology

Calendar

Mar. 17 - Q4 2025 Earnings Call

More about the company